To ask the Scottish Executive how it will ensure that women taking hormone replacement therapy or the contraceptive pill are forewarned of the possible risk of thrombosis associated with such medication.
In primary care, the risks and benefits of any prescribed medication are discussed during consultation between the patient and their GP. This would include the risks of thrombosis associated with hormone replacement therapy (HRT) and the contraceptive pill, which are well-known.
Pharmacists will discuss the indications, contra-indications, drug interactions and side effects with the patient before dispensing medication. There is also a legal requirement for each prescription for HRT and the oral contraceptive pill to contain an information leaflet which describes product characteristics, including the risk of thrombosis.
We would also expect clinicians providing maternity services to assess pregnant women for risk factors for DVT as part of their clinical assessment, and to provide further management in line with the current clinical guidelines produced by SIGN and the Royal College of Obstetricians and Gynaecologists.
In addition, we have commissioned Lifeblood, the thrombosis charity, to develop a general information leaflet on DVT. The leaflet includes guidance for individuals considered to be at high risk, including those on HRT and the oral contraceptive pill, and mentions that a simple blood test is available which may show a genetic susceptibility to DVT. The leaflet has been distributed to every GP practice in Scotland so that it can be on display and available to the general public.